Renal amyloidosis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
| Line 29: | Line 29: | ||
===Region=== | ===Region=== | ||
* | *ALECT2 is more frequent in the United States area.<ref name="pmid23704299">{{cite journal |vauthors=Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, Herrera Hernandez L, Vrana JA, Theis JD, Quint PS, Dogan A, Nasr SH |title=Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases |journal=Clin J Am Soc Nephrol |volume=8 |issue=9 |pages=1515–23 |date=September 2013 |pmid=23704299 |pmc=3805078 |doi=10.2215/CJN.10491012 |url=}}</ref> | ||
*AFib cases are most reported in Europe countries. | |||
=== | |||
=== | |||
==References== | ==References== | ||
Revision as of 00:05, 19 June 2018
|
Renal amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Template:Renal amyloidosis On the Web |
|
American Roentgen Ray Society Images of Renal amyloidosis epidemiology and demographics |
|
Risk calculators and risk factors for Renal amyloidosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- In renal amyloidosis, is usually first diagnosed in average age of 65 years.[1]
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- In renal amyloidosis, the male to female ratio is approximately 2 to 1.[1]
Region
- ALECT2 is more frequent in the United States area.[2]
- AFib cases are most reported in Europe countries.
References
- ↑ 1.0 1.1 Khalighi MA, Dean Wallace W, Palma-Diaz MF (April 2014). "Amyloid nephropathy". Clin Kidney J. 7 (2): 97–106. doi:10.1093/ckj/sfu021. PMC 4377792. PMID 25852856.
- ↑ Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, Herrera Hernandez L, Vrana JA, Theis JD, Quint PS, Dogan A, Nasr SH (September 2013). "Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases". Clin J Am Soc Nephrol. 8 (9): 1515–23. doi:10.2215/CJN.10491012. PMC 3805078. PMID 23704299.